MK-8353

P1, N=111, Terminated, Merck Sharp & Dohme LLC | Completed --> Terminated; business reasons.

MK-8353/selumetinib 50/25 mg and 100/50 mg had acceptable safety and tolerability, whereas 150/75 mg was not tolerable. No responses were observed.

This study provided evidence that FBXW7 loss of function promoted ESCC via MAP4 overexpression and ERK phosphorylation, and this novel FBXW7/MAP4/ERK axis may be an efficient target for ESCC treatment.

P1, N=110, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=182 --> 110

P1, N=182, Active, not recruiting, Merck Sharp & Dohme Corp. | Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Sep 2022 | Trial primary completion date: Mar 2023 --> Sep 2022

P1, N=182, Recruiting, Merck Sharp & Dohme Corp. | N=96 --> 182

P1, N=96, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Oct 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Mar 2023

The best treatments include the combination of B-Raf and MEK inhibitors (dabrafenib and trametinib, encorafenib and binimetinib, vemurafenib and cobimetanib)...Ulixertinib, MK-8353, and GDC-0994 are orally effective, potent, and specific inhibitors of ERK1/2 that are in early clinical trials for the treatment of various advanced/metastatic solid tumors...The decrease in RSK phosphorylation appears to be a result of ERK inhibition and the decrease in ERK1/2 phosphorylation is related to the inability of MEK to catalyze the phosphorylation of the ERK-MK-8353 complex; these decreases characterize the ERK dual mechanism inhibition paradigm. Additional work will be required to determine whether ERK inhibitors will be successful in the clinic and are able to forestall the development of drug resistance of the MAP kinase pathway.